They enrolled NSCLC patients with a documented high genomic loss of heterozygosity (LOH) or known BRCA1/2 mutations who had disease progression on standard platinum-based or anti-PD-(L)1 therapy. The gene discussed is BRCA1; the disease is non-small cell lung carcinoma.